Pharma Focus Asia

BeiGene Opens New Manufacturing Facility in New Jersey

Introduction:

BeiGene plans to open new manufacturing site and R&D center for the development of advanced new medicines.

Features:

The new state-of-the-art manufacturing site is laid in 42-acre site. The initial phase of the construction is designed with several hundred million dollars. Moreover, it has more than one million square feet of developable real estate for potential future expansion.

The establishment of this new facility will advance impactful treatments by making it more accessible to patients around the world. In addition, the medicines will be manufactured in the new facility.

This 400,000 square feet will be completely dedicated for commercial-stage biologic pharmaceutical manufacturing consisting of 16,000 liters of biologics capacity accompanied with clinical R&D and office space.

The construction of the manufcaturing facility is expected to start in 2022 and be completed in late-2023 or in 2024.

Specifications:

NameBeiGene
TypeNew Construction
Year2024

 

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference